Navigation Links
BioMarin Announces First Quarter 2011 Financial Results
Date:4/28/2011

ause it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan, Aldurazyme and Firdapse and development of its pipeline.  By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future.  Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes and uses the adjusted EBITDA methodology in establishing corporate goals for internal compensation programs.

Diluted Earnings Per Share Calculation As of March 31, 2011 and March 31, 2010, the shares related to our outstanding convertible debt are 19.1 million and 26.3 million, respectively. The calculation of non-GAAP adjusted EBITDA diluted earnings per share for the quarter ended March 31, 2011 and March 31, 2010 includes the 19.1 million shares and the 10.3 million shares, respectively, related to the company's convertible debt, as their impact is considered dilutive.

Conference Call DetailsBioMarin will host a conference call and webcast to discuss first quarter 2011 financial results today, Thursday, April 28, at 5:00 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.BMRN.com.

Date: April 28, 2011
Time: 5:00 p.m. ET
U.S. / Canada Dial-in Number:  888.396.2386
International Dial-in Number:  617.847.8712
Participant Code: 42725170
Replay Dial-in Number: 888.286.8010
Replay International Dial-in Number: 617.801.6888
Replay Code: 56138656

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio compris
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... Dec. 11, 2014 Research and Markets ... of the "Drug Injection Devices to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 As new ... expanding list of health conditions, drug developers have ... the administration process and increase the efficiency and ...
(Date:12/13/2014)... Dec. 12, 2014  Radiologists can transmit their ... to their referring physicians, electronic health records (EHR) ... selected technology.  That was the ... Corporation (ADS) at the recent Radiology Society of ... of radiology reports in this manner also helps ...
(Date:12/13/2014)... Dec 12, 2014 Mindray Medical International Limited ... manufacturer and marketer of medical devices worldwide, today announced ... shareholders held in Hong Kong ... Mindray shareholders voted to re-elect incumbent directors Li Xiting ... Mindray,s shareholders did not re-elect Peter Wan ...
Breaking Medicine Technology:Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 3Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2
... June 30, 2011 Endo Pharmaceuticals (Nasdaq: ENDP ... comparing the novel investigational drug axomadol against placebo in the ... pain. The results indicate that axomadol did not meet predetermined ... of the data and evaluating the path forward for the ...
... YORK, June 30, 2011 Reportlinker.com announces that ... its catalogue: Medical Devices & ... http://www.reportlinker.com/p0565215/Medical-Devices--Diagnostics-Equipments-in-India.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics By 2014, the Indian ... reach US$ 6.41 million, growing 15.5% annually. ...
Cached Medicine Technology:Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain 2Medical Devices & Diagnostics Equipments in India 2Medical Devices & Diagnostics Equipments in India 3Medical Devices & Diagnostics Equipments in India 4Medical Devices & Diagnostics Equipments in India 5
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
(Date:12/17/2014)... parents should leave prenatal picture-taking to medical professionals, the ... ultrasound imaging and heartbeat monitors to get "keepsake" images ... "Although there is a lack of evidence ... monitors, prudent use of these devices by trained health ... engineer, said in an agency news release. "Ultrasound ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... the holiday party season fast approaching, a new study reveals ... DUI arrests have fewer drunk drivers on their roads. ... more vigilantly are better able to deter inebriated revelers from ... any new laws are being passed regarding drinking and driving," ...
(Date:12/15/2014)... 15, 2014 A recent survey found ... women as impacting skin health and beauty were: “Connections,” ... skin care.” Water and health advocate and radio host ... article describing the survey and the Four C’s.* Kleyne ... every category discussed would benefit from paying attention to ...
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... Mass., July 29 - Boston Scientific Corporation (NYSE: BSX ... Katharine T. Bartlett and Bruce L. Byrnes as Directors. ... Pye Professor of Law at the Duke University School of Law, ... through a period of major strategic expansion. During Bartlett,s tenure ...
... , NEW ORLEANS, July 29 ... its pioneering spirit again by leading the way to making healthy alternatives ... , , Consumers in Tokyo will be the first ... the first store planned to open in 2010. Japan makes sense as ...
... BATESVILLE, Ind., July 29 Hillenbrand, Inc. (NYSE: HI ... Wednesday, Aug. 12, 2009. The full text of the release and ... www.HillenbrandInc.com . , , The company ... financial analysts the same day at 8 a.m. ET. During the ...
... EMERYVILLE, Calif., July 29 Bionovo, Inc. (Nasdaq: BNVI ... needs in women,s health and oncology, today announced that Dr. Mary ... President and CFO, will be presenting at the BMO Capital Markets ... Wednesday, August 5, 2009. The event will be held at the ...
... , SOUTH SAN FRANCISCO, Calif., July 29 ... biopharmaceutical company focused on innovative oncology therapies, today announced that ... to provide a corporate overview, including a discussion about the ... at two upcoming investor conferences: , , ...
... half in study of Finnish men , WEDNESDAY, July 29 ... high-intensity exercise appears to reduce the risk of cancer, a ... men, aged 42 to 61, whose leisure-time physical activity was ... history of cancer, according to the report published online July ...
Cached Medicine News:Health News:Boston Scientific Announces Election of Katharine Bartlett and Bruce Byrnes to Its Board of Directors 2Health News:Boston Scientific Announces Election of Katharine Bartlett and Bruce Byrnes to Its Board of Directors 3Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 2Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 3Health News:Hillenbrand Announces Third-Quarter Earnings Release Date and Conference Call 2Health News:Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference 2Health News:Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August 2
Titanium. Straight shafts with 6.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.4 inches....
Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches....
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches....
Curved shafts and tips with 6 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches....
Medicine Products: